IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2950
-0.0188 (-5.99%)
Apr 25, 2025, 4:00 PM EDT - Market closed
IGC Pharma Revenue
IGC Pharma had revenue of $257.00K in the quarter ending December 31, 2024, with 25.98% growth. This brings the company's revenue in the last twelve months to $1.24M, up 1.64% year-over-year. In the fiscal year ending March 31, 2024, IGC Pharma had annual revenue of $1.35M with 47.64% growth.
Revenue (ttm)
$1.24M
Revenue Growth
+1.64%
P/S Ratio
17.59
Revenue / Employee
$18,448
Employees
67
Market Cap
23.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | 4.07M | -1.04M | -20.41% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
IGC News
- 1 day ago - IGC Pharma Welcomes Strategic Investment from Advisors - Accesswire
- 4 days ago - IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs - Accesswire
- 17 days ago - IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program - Accesswire
- 24 days ago - IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health - Accesswire
- 4 weeks ago - IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances - Accesswire
- 5 weeks ago - IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences - Accesswire
- 5 weeks ago - IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida - Accesswire
- 6 weeks ago - IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. - Accesswire